DUKORAL® EFFICACY
Protective efficacy has been evaluated in mass vaccination campaigns and large clinical trials across three continents. Protective efficacy was determined by mathematical modelling. These campaigns and trials have shown that DUKORAL® provides 78–86% protection against cholera in adults.1–5
*The protective efficacy of oral B subunit killed whole-cell (BS-WC) and killed whole-cell (WC) cholera vaccines was assessed in a placebo-controlled, randomised, double-blind study of 63,498 Bangladeshi children aged 2–15 years and women aged over 15 years. Protective efficacy (PE) was estimated as: PE=1-[Proportion of vaccinees ill with cholera]/[Proportion of controls ill with cholera].3
**The PE of oral inactivated whole-cell/recombinant-B-subunit (WC/rBS) cholera vaccine was assessed in a placebo-controlled, randomised, double-blind study of 1,563 Peruvian military recruits. PE was estimated as: PE=([Proportion of controls ill with cholera]-[Proportion of vaccinees ill with cholera])/[Proportion of controls ill with cholera]x100.2
†Following a mass-immunisation programme with a two-dose regimen of WC-rBS vaccine, vaccine effectiveness was assessed in 43 persons with cholera and 172 controls during a cholera outbreak in Beira, Mozambique. PE was estimated as: PE=(1-[adjusted odds ratio])x100. Odds ratios were adjusted for: consumption of uncooked food, consumption of dried fish, consumption of food away from home, ownership of multiple kitchen implements, access to a water tap, and residence in a household with electricity.4
‡Following the receipt of two doses of killed BS-WC cholera vaccine in 23,291 individuals aged two years and older, in six rural and urban sites, efficacy was assessed during an outbreak of cholera. PE was estimated as: PE=(1-adjusted relative risk)x100.5
DUKORAL® IS GENERALLY WELL TOLERATED AND CAN OFFER PROTECTION AGAINST CHOLERA
DUKORAL® has a generally well tolerated safety profile in widespread clinical studies among adults and children, as well as over 30 years of real-world experience.1,7
ADVERSE EVENTS
The most frequently reported adverse reactions relating to DUKORAL® include gastrointestinal symptoms such as abdominal pain, cramps, gurgling, discomfort, diarrhoea and headaches. These adverse events occurred at similar frequency in placebo groups.1
The table below shows the most common adverse events:1
Adverse reactions are listed according to the following frequency categories:
• Very common: 1/10
• Common: 1/100 to <1/10
• Uncommon: 1/1000 to <1/100
• Rare: 1/10 000 to <1/1000
• Very rare: <1/10 000
Rare and very rare adverse reactions can be found in the SmPC.
LEARN MORE ABOUT DUKORAL®
Delve deeper into the product features, clinical findings, and dosing recommendations.
DUKORAL® suspension and effervescent powder for oral suspension
OVERVIEW
Get a useful overview of DUKORAL®, including key facts about the vaccine.
DUKORAL® suspension and effervescent powder for oral suspension
DOSING & ADMINISTRATION
DUKORAL® is administered orally in two doses for adults, and three for children <6 years.
References
- DUKORAL®. Summary of Product Characteristics. February 2023. Available at: https://www.medicines.org.uk/emc/product/5087/smpc. Accessed: August 2026.
- Clemens J, Harris J, Khan MR, et al. Field trial of oral cholera vaccines in Bangladesh. The Lancet. 1986;328(8499):124-127.
- Sanchez JL, Vasquez B, Begue RE, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. The Lancet. 1994;344(8932):1273-1276.
- Lucas MES, Deen JL, Von Seidlein L, et al. Effectiveness of Mass Oral Cholera Vaccination in Beira, Mozambique. N Engl J Med. 2005;352(8):757-767.
- Khatib AM, Ali M, Von Seidlein L, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. The Lancet Infectious Diseases. 2012;12(11):837-844.
- NaTHNaC Travel Health Pro. Cholera. August 2024. Available at: https://travelhealthpro.org.uk/factsheet/56/cholera. Accessed: August 2026.
- Holmgren J. Modern History of Cholera Vaccines and the Pivotal Role of icddr,b. J Infect Dis. 2021;224(Suppl 7):S742-S748.
UK-DUK-2600001 (v2.0) August 2026